Scientists investigating links between blood cancers and Alzheimer’s disease identified a shared mutation pathway that could eventually support early dementia screening through ordinary blood draws.
Researchers said certain genetic alterations associated with hematologic malignancies may trigger overly inflammatory immune cells in the brain, accelerating neurodegeneration through pathways not previously targeted in Alzheimer’s drug development.
Neurologists cautioned that any clinical screening tool remains years away, but the biological overlap suggests oncology and dementia research fields may converge on common therapeutic targets.
If validated in larger trials, a blood-based test could help clinicians intervene earlier when lifestyle, cardiovascular and anti-inflammatory strategies may still slow cognitive decline.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/